- Home
- NPWR vs ARCT Comparison
NPWR vs ARCT Comparison
Compare NPWR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- ARCT
- Stock Information
- Founded
- NPWR 2010
- ARCT 2013
- Country
- NPWR United States
- ARCT United States
- Employees
- NPWR N/A
- ARCT N/A
- Industry
- NPWR Industrial Machinery/Components
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- ARCT Health Care
- Exchange
- NPWR Nasdaq
- ARCT Nasdaq
- Market Cap
- NPWR 743.1M
- ARCT 602.7M
- IPO Year
- NPWR N/A
- ARCT N/A
- Fundamental
- Price
- NPWR $9.88
- ARCT $15.76
- Analyst Decision
- NPWR Hold
- ARCT Strong Buy
- Analyst Count
- NPWR 2
- ARCT 7
- Target Price
- NPWR $9.50
- ARCT $65.00
- AVG Volume (30 Days)
- NPWR 725.1K
- ARCT 380.6K
- Earning Date
- NPWR 11-11-2024
- ARCT 11-07-2024
- Dividend Yield
- NPWR N/A
- ARCT N/A
- EPS Growth
- NPWR N/A
- ARCT N/A
- EPS
- NPWR 0.11
- ARCT N/A
- Revenue
- NPWR $250,000.00
- ARCT $160,399,000.00
- Revenue This Year
- NPWR N/A
- ARCT $6.91
- Revenue Next Year
- NPWR $7,100.29
- ARCT $5.24
- P/E Ratio
- NPWR $93.31
- ARCT N/A
- Revenue Growth
- NPWR 38.12
- ARCT N/A
- 52 Week Low
- NPWR $6.57
- ARCT $14.93
- 52 Week High
- NPWR $14.28
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- NPWR 41.66
- ARCT 37.77
- Support Level
- NPWR $9.51
- ARCT $15.55
- Resistance Level
- NPWR $11.26
- ARCT $20.92
- Average True Range (ATR)
- NPWR 0.71
- ARCT 1.11
- MACD
- NPWR -0.32
- ARCT -0.17
- Stochastic Oscillator
- NPWR 9.76
- ARCT 4.56
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.